* Images used are not actual patients
NEPHROSCAN®
FDA APPROVED: NEPHROSCAN®(Kit for the Preparation of Technetium Tc 99m Succimer Injection)
Indication: NEPHROSCAN®, after radiolabeling with technetium Tc 99m, is a radioactive diagnostic agent indicated for use as an aid in the scintigraphic evaluation of renal parenchymal disorders in adults and pediatric patients including term neonates.
Important Safety Information:
Hypersensitivity Reactions: Hypersensitivity reactions, including urticaria, rash, pruritus, and erythema have been reported with the use of technetium Tc 99m succimer injection in adults and pediatric patients. The time of onset of the reactions varied within 2 hours to several hours after the injection. Have appropriate instruments and medications necessary for immediate treatment of hypersensitivity reactions and monitor patients for reactions during and after administration.
Radiation Risks: TechnetiumTc 99m succimer injection contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care workers. Advise patients to hydrate before and after administration and to void frequently after administration.
Risk in Patients with Advanced Renal Failure: The use of technetium Tc 99m succimer injection in patients with severely reduced estimated glomerular filtration (eGFR) may have an effect on image interpretation as the kidneys may not absorb the technetium Tc 99m succimer and thus the Tc 99m succimer may distribute to organs or parts of the body other than the kidneys. It has been reported that satisfactory images may be obtained in some of these patients by delaying imaging between 6 hours to 24 hours.
Learn more at: nephroscan.com
For important risk and use information, please see Full Prescribing Information.
NEPHROSCAN® is a Product of Theragnostics Inc., an Ariceum Therapeutics company